Allergy Therapeutics
plc
("Allergy
Therapeutics", or the "Group")
Exercise of Options and Total
Voting Rights
19
December 2024 Allergy Therapeutics
(AIM: AGY), the fully integrated commercial biotechnology company
specialising in allergy immunotherapies, announces that to rectify
an administrative oversight in relation to the exercise of options
under the Company's block admission facility, the Company has made
an application to the London Stock Exchange for 709,638 ordinary
shares of 0.1 pence each to be admitted to trading on AIM. It is
expected that these shares will be admitted to trading on AIM on or
around 27 December 2024.
The Group's total issued ordinary
share capital remains unchanged at 4,766,439,938 ordinary shares,
with no shares held in treasury. This figure may be used by
shareholders as the denominator for their calculations regarding
disclosure obligations.
For
further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
Geoff Nash /Giles Balleny/ Seamus
Fricker / Rory Sale
Nigel Birks - Life Science Specialist
Sales
Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR
Healthcare
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the
potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. For more information, please see
www.allergytherapeutics.com.